Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 145 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H1 2015', provides an overview of the Metastatic Adenocarcinoma of The Pancreas's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Adenocarcinoma of The Pancreas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Adenocarcinoma of The Pancreas and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Adenocarcinoma of The Pancreas
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Metastatic Adenocarcinoma of The Pancreas and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Metastatic Adenocarcinoma of The Pancreas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Adenocarcinoma of The Pancreas pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Adenocarcinoma of The Pancreas
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Adenocarcinoma of The Pancreas pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Metastatic Adenocarcinoma of The Pancreas Overview 9
Therapeutics Development 10
Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Overview 10
Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis 11
Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Development by Companies 12
Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Investigation by Universities/Institutes 15
Metastatic Adenocarcinoma of The Pancreas - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Metastatic Adenocarcinoma of The Pancreas - Products under Development by Companies 18
Metastatic Adenocarcinoma of The Pancreas - Products under Investigation by Universities/Institutes 20
Metastatic Adenocarcinoma of The Pancreas - Companies Involved in Therapeutics Development 21
Aduro BioTech, Inc. 21
Amgen Inc. 22
Axcentua Pharmaceuticals AB 23
BioCancell Therapeutics, Inc. 24
Boehringer Ingelheim GmbH 25
Boston Biomedical, Inc. 26
Eleison Pharmaceuticals, Inc. 27
Gilead Sciences, Inc. 28
Halozyme Therapeutics, Inc. 29
Incyte Corporation 30
Millennium Pharmaceuticals, Inc. 31
Nanotherapeutics, Inc. 32
NewLink Genetics Corporation 33
Novartis AG 34
Phoenix Biotechnology, Inc. 35
Sanofi 36
Teva Pharmaceutical Industries Limited 37
Threshold Pharmaceuticals, Inc. 38
Metastatic Adenocarcinoma of The Pancreas - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
AXP-10711 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
BBI-608 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
BC-819 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
BI-853520 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
binimetinib - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
CEP-37250 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
CRS-207 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Dendritic Cell Therapy for Cancer - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
erismodegib - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
evofosfamide - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
ganitumab - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
glufosfamide - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
indoximod - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
LGK-974 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
MesoCART - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
MLN-0264 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
paclitaxel lipsomal - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
PBI-05204 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
PEGPH-20 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
plerixafor - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
PRI-724 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
ruxolitinib phosphate - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
SiG12D-LODER - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
simtuzumab - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Stem Cell Therapy for Oncology - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Triapine - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Metastatic Adenocarcinoma of The Pancreas - Recent Pipeline Updates 105
Metastatic Adenocarcinoma of The Pancreas - Dormant Projects 141
Metastatic Adenocarcinoma of The Pancreas - Discontinued Products 142
Metastatic Adenocarcinoma of The Pancreas - Product Development Milestones 143
Featured News & Press Releases 143
Nov 03, 2014: Threshold Pharmaceuticals' Partner Merck KGaA Completes Target Enrollment in the TH-302 Phase 3 MAESTRO Study in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma 143
Appendix 144
Methodology 144
Coverage 144
Secondary Research 144
Primary Research 144
Expert Panel Validation 144
Contact Us 144
Disclaimer 145

List of Tables
Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas, H1 2015 10
Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Development by Companies, H1 2015 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2015 15
Comparative Analysis by Late Stage Development, H1 2015 16
Comparative Analysis by Clinical Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Development by Companies, H1 2015 (Contd..1) 19
Products under Investigation by Universities/Institutes, H1 2015 20
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Aduro BioTech, Inc., H1 2015 21
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Amgen Inc., H1 2015 22
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Axcentua Pharmaceuticals AB, H1 2015 23
Metastatic Adenocarcinoma of The Pancreas - Pipeline by BioCancell Therapeutics, Inc., H1 2015 24
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Boehringer Ingelheim GmbH, H1 2015 25
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Boston Biomedical, Inc., H1 2015 26
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Eleison Pharmaceuticals, Inc., H1 2015 27
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Gilead Sciences, Inc., H1 2015 28
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Halozyme Therapeutics, Inc., H1 2015 29
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Incyte Corporation, H1 2015 30
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 31
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Nanotherapeutics, Inc., H1 2015 32
Metastatic Adenocarcinoma of The Pancreas - Pipeline by NewLink Genetics Corporation, H1 2015 33
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Novartis AG, H1 2015 34
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Phoenix Biotechnology, Inc., H1 2015 35
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Sanofi, H1 2015 36
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 37
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 38
Assessment by Monotherapy Products, H1 2015 39
Number of Products by Stage and Target, H1 2015 41
Number of Products by Stage and Mechanism of Action, H1 2015 43
Number of Products by Stage and Route of Administration, H1 2015 45
Number of Products by Stage and Molecule Type, H1 2015 47
Metastatic Adenocarcinoma of The Pancreas Therapeutics - Recent Pipeline Updates, H1 2015 105
Metastatic Adenocarcinoma of The Pancreas - Dormant Projects, H1 2015 141
Metastatic Adenocarcinoma of The Pancreas - Discontinued Products, H1 2015 142